Valvular heart disease and Covid 19
Keywords:
Valve disease, Covid 19, heart, cardiovascular.Abstract
Heart valve diseases are pathologies of great importance in medical care, this article will
describe the pathophysiology, epidemiology and its association with Covid 19. During
the pandemic, difficulties were found in the care of patients with these diseases since
the diagnostic tests that they were practiced generating aerosols which produced
an imminent risk of contagion to health professionals, therefore telemedicine and
telephone follow-up were vital in the follow-up of patients with valve disease. On the
other hand, Covid 19 generated great cardiac affectation in many individuals, among
whom the generation of thrombi and generating immunosuppression are described,
making people with heart valves susceptible to obstructions and infections such as
endocarditis, on many occasions’ emergency surgery was indicated.
References
Vahanain A, Beyersdorf F, Milojevic M, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2022;43(7):561-632.
Radke R, Frenzel T, Baumgartner H, Diller G. Adult congenital heart disease.
COVID-19 pandemic. Heart 2020;106(17):1302-1309 Available from: http://dx.doi.org/10.1136/heartjnl-2020-317258
Mrsic Z, Hopkins S, Antevil J, Mukkenix P. Valvular Heart Disease Prim Care. 2018; 45(1):81-94. Available from: 10.1016/j.pop.2017.10.002
Khanduri A, Anand U, Doss M, Lovett L. Severe acute mitral valve regurgitation in a COVID-19-infected patient. BMJ case reports. 2021;14(1):1-6 Available from: 10.1136/bcr-2020-239782
Dvir D, Simonato M, Amat-Santos I, Amabile N, Et al. Severe Valvular Heart Disease and COVID-19: Results from the Multicenter International Valve Disease Registry. Structural Heart. 2021;5(4):424-426 Available from: https://doi.org/10.1080/24748706.2021.1908646
Ebeid k, Abdullah M, Muneeb A, Braiteh N, Shailesh F, Ali M. The tunnel-vision effect of covid-19: an incidental discovery of severe bicuspid aortic valve stenosis. Chest journal . 2021;160(4):170A-171A. Available from: https://doi.org/10.1016/j.chest.2021.07.190
Balfe C, O’Connor C, Giblin G, Et al. Presentation of Severe Rheumatic Mitral Stenosis at the Peak of the COVID-19 Pandemic and the Presumptive Treatment as Severe Coronavirus Illness. Eur J Case Rep Intern Med. 2020;7(12):1-5 Available from: 10.12890/2020_001957
Debiasi R, Harahsheh A, Sirinivasalu H, et al. Multisystem Inflammatory Syndrome of Children: Subphenotypes, Risk Factors, Biomarkers, Cytokine Profiles, and Viral Sequencing. The journal of pediatrics. 2021;237(18):125-135. Available from: https://doi.org/10.1016/j.jpeds.2021.06.00
Henderson L, Canna S, Friedman K, et al. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumato. 2021;73(4):13-29. Available from: https://doi.org/10.1002/art.41616
Soler J, Galve E. Worldwide perspective of valve disease. Heart. 2000;83: 721-725. Available from: https://doi.org/10.3389/fcvm.2020.602271
Huntley G, Thaden J, Nkomo T. Epidemiology of heart valve disease. Principles of Heart Valve Engineeringy. 2019;41-42 Available from: https://doi.org/10.1016/B978-0-12-814661-3.00003-4
Rostagno C. Heart valve disease in elderly. World J Cardiol. 2019;11(2):71-83. Available from: 10.4330/wjc.v11.i2.71
Ahmed S, Mohan P, Jabbour, Et al. COVID-19 and its impact on the cardiovascular system. Open Heart. 2021;8(1):1-8. Available from: 10.1136/openhrt-2020-001472
Pascual V, Canton T, Hernando L, Pajin L, Et al. Impacto de la covid-19 en la mortalidad en pacientes con estenosis aórtica grave: análisis basado en inteligencia artificial. Interv. Cardio. 2021;3(4):C6-C25 Available from: https://doi.org/10.24875/RECIC.M21000235
Gisbert G, Vidal V, Moruno M, Et al. Bioprosthetic Valve Thrombosis and Obstruction Secondary to COVID-19. Can J Cardiol. 2020;37(6):938.e3-938.e6. Available from: https://doi.org/10.1016/j.cjca.2020.10.008
Sanders D, Sutter J, Tatooles A, Et al. Endocarditis Complicated by Severe Aortic Insufficiency in a Patient with COVID-19: Diagnostic and Management Implications. Case Report in Cardiology. 2020;2020:1-4. Available from: https://doi.org/10.1155/2020/8844255
Lipczyńska M, Kowalik.E, Kumor M, Et al. Predictors of COVID-19 outcomes in adult congenital heart disease patients-anatomy versus function. Polish Heart Journal. 2021;80(2):151-155. Available from: 10.33963/KP.a2021.0176
Passos L, Carmo M, Aikawa E. Rheumatic Heart Valve Disease Pathophysiology and Underlying Mechanisms. Frontiers in Cardiovascular Medicine. 2021;11:1-7. Available from: https://doi.org/10.3389/fcvm.2020.612716
Sukumar J, Barsouk A, Saginala K, Et al. Valvular Heart Disease Epidemiology. Med Sci. 2022;10:1-12. Available from: https://doi.org/10.1038/s41569-021-00570-z
Côté N, Annick M. Sex Differences in the Pathophysiology, Diagnosis, and Management of Aortic Stenosis. Cardiology Clinics. 2020;38(1):129-138. Available from: https://doi.org/10.1016/j.ccl.2019.09.008
Frey N, Steeds R, Rudolph T Et al. Symptoms, disease severity and treatment of adults with a new diagnosis of severe aortic stenosis. Heart. 2019;105(22):1709-1716. Available from: 10.1136/heartjnl-2019-314940
Aghagoli G, Gallo B, Et al. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review. Journal of Cardiac Sugery. 2020;35(6):1302-1305. Available from: https://doi.org/10.1111/jocs.14538
Libby P. The Heart in COVID-19: Primary Target or Secondary Bystander?. JACC: Basic to Translational Scienc. 2020;5(5):537-542. Available from: https://doi.org/10.1016/j.jacbts.2020.04.001
Tajbakhsh A, Gheibi S, Taghizadeh H, Et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment and follow. up Expert Rev Anti Infect Ther. 2021;19(3):345-357. Available from: 10.1080/14787210.2020.1822737
Bartoli F, Aikawa E. Heart Valve Disease: Challenges and New Opportunities. Frontiers in Cardiovascular Medicine. 2020;7:1-5. Available from: https://doi.org/10.3389/fcvm.2020.602271
Wang X, Gao H, Zhang Z, et al. Effect of the COVID-19 pandemic on complications and mortality of patients with cardiac surgery. J Cardiothorac Surg. 2021;16(1):1-9. Available from: 10.1186/s13019-021-01744-z
Kodali S, Velagapudi P, Hahn R, Aboot D, Et al. Valvular Heart Disease in Patients ≥80 Years of Age. Journal of the American College of Cardiology. 2018;71(18):2058-2072. Available from: https://doi.org/10.1016/j.jacc.2018.03.459.
Buitrago C, Gutierrez A, Jimenez D, Aristizabal C. Mechanical Valve Thrombosis Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Case Report. Cureus. 2022;14(3):1-5. Available from: 10.7759/cureus.23358
Alexander S, Fergus I, Lerakis S. Bioprosthetic Valve Thrombosis Associated With COVID-19 Infection. Circ Cardiovasc Imaging. 2021;14(5):452-454. Available from: 10.7759/cureus.23358
Vinnakota S, Jentzer J, Luis S. Bioprosthetic Thrombolysis for COVID-19-associated bioprosthetic mitral valve thrombosis with shock. Eur Heart J. 2021;42(39):4093. Available from: 10.1093/eurheartj/ehab333
Yuan N, Wu S, Rader F, Siegel R. Determining Which Hospitalized Coronavirus Disease 2019 Patients Require Urgent Echocardiography. J Am Soc Echocardiogr. 2021;34(8): 831-838. Available from: 10.1016/j.echo.2021.03.010
Vasudev R, Gurafay N, Habib H, Et al. The utility of bedside echocardiography in critically ill COVID-19 patients: Early observational findings from three Northern New Jersey hospitals. Echocardiography. 2020;37(9):1362-1365. Available from: https://doi.org/10.1111/echo.14825
Pellegrini D, Kawakami R, Guagliumi G, et al. Microthrombi as a Major Cause of Cardiac Injury in COVID-19. Circulation. 2021;143:1031-1042. Available from: https://www.ahajournals.org/doi/pdf/10.1161/CIRCULATIONAHA.120.051828
Cooke J, Connor J, Jain A, Acute and Chronic Cardiovascular Manifestations of COVID-19: Role for Endotheliopathy. Methodist Debakey Cardiovasc J. 2021;17(5): 53-62. Available from: 10.14797/mdcvj.1044
Fogarty H, Towsend L, Ni Cheallaigh C, Bergin C Et al. More on COVID-19 coagulopathy in Caucasian patients. British Journal of Haematology. 2020;189(6):1060-1061. Available from: https://doi.org/10.1111/bjh.16791
Moriarty P, Gorby L, Stroes E, Kastelein J, et al Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. Current Atherosclerosis Reports. 2020;22(48):1-8. Available from: https://doi.org/10.1007/s11883-020-00867-3
Shafi A, Shaikh S, Shirke M, et al Cardiac Manifestations in COVID-19 patients—A systematic review. Journal of Cardiac Surgery. 2020;35(8):1988- 2008. Available from: https://doi.org/10.1111/jocs.14808
Masumoto A, Kitai T, Matsumoto S, Et al. Impact of serum lactate dehydrogenase on the short-term prognosis of COVID-19 with pre-existing cardiovascular diseases. Journal of Cardiology. 2022;79(4):501-508. Available from: https://doi.org/10.1016/j.jjcc.2021.12.014
Jafari M, Tayeb S, Ebadi A, et al. Incidence of cardiac complications following COVID-19 infection: An umbrella meta-analysis study. Heart and Lung. 2022;52:136-145. Available from: https://doi.org/10.1016/j.hrtlng.2022.01.001
Zhang B, Xu H, Zhang H, Et al. Prognostic Value of N-Terminal Pro–B-Type Natriuretic Peptide in Elderly Patients With Valvular Heart Disease. J Am Coll Cardiol. 2020; 75(14):1659-1672. Available from: https://www.jacc.org/doi/full/10.1016/j.jacc.2020.02.031
Baumgartneer H, Lung B, Otto C. Timing of intervention in asymptomatic patients with valvular heart disease. European Heart Journal. 2020;41(45):4349-4356. Available from: https://doi.org/10.1093/eurheartj/ehaa485
Dominik W, Nee S, Sandy N, Marschollek M. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection. 2021;49:15-28. Available from: https://doi.org/10.1007/s15010-020-01509-1
Chen H, Enger J, Thanassoulis G. Risk factors for valvular calcification. Curr Opin Endocrinol Diabetes Obes. 2019;26(2):96-102. Available from: 10.1097/MED.0000000000000471
Hani M, Elsayed M, Moody W, Et al. Echocardiographic Findings in Patients With COVID-19 Pneumonia. Canadian Journal of Cardiology. 2020;36(8):1203-1207. Available from: https://doi.org/10.1016/j.cjca.2020.05.030
Sattar Y, Ullah W, Rauf H, et al. COVID-19 cardiovascular epidemiology, cellular pathogenesis, clinical manifestations and management. IJC Heart & Vasculature. 2020;29:1-8. Available from: https://doi.org/10.1016/j.ijcha.2020.100589
Hillesheim T, Baldissera J, Galletti V, Et al. Heparin and its contribution to the treatment of COVID-19. Research, Society and Development. 2021;10(12):1-15. Available from: https://doi.org/10.33448/rsd-v10i12.20274
Andreini D, Conte E, Mushtaq S, Et al. Extent of lung involvement over severity of cardiac disease for the prediction of adverse outcome in COVID-19 patients with cardiovascular disease. International Journal of Cardiology. 2021;323:292-294. Available from: https://doi.org/10.1016/j.ijcard.2020.10.006
Crousillat D, Wood M. Valvular Heart Disease and Heart Failure in Women. Heart Failure Clinics. 2019;15(1):77-85. Available from: https://doi.org/10.1016/j.hfc.2018.08.008
Taylor C, Ordoñez J, Jones N, et al Survival of people with valvular heart disease in a large, English community-based cohort study. Heart. 2021;106(16):1336-1342. Available from: 10.1136/heartjnl-2020-318823
Ogbemudia E, Umuerri E, Relevance of Rheumatic Valvular Heart Disease in the Aetiology of Heart Failure in Contemporary Times. West Afr J Med. 2021;38(3):241-245. Available from: https://pubmed.ncbi.nlm.nih.gov/33765372/
Chambers J. Valve disease and non-cardiac surgery. Heart. 2018;104:1878-1887. Available from: http://dx.doi.org/10.1136/heartjnl-2017-312455.
Downloads
Published
Versions
- 2025-11-17 (3)
- 2025-08-13 (2)
- 2022-09-20 (1)
How to Cite
Issue
Section
License
Copyright (c) 2022 Scientific and Eduaction Medical JournalAtribución – No comercial – Compartir igual: Esta licencia permite a otros distribuir, remezclar, retocar, y crear a partir de tu obra de modo no comercial, siempre y cuando te den crédito y licencien sus nuevas creaciones bajo las mismas condiciones.
Attribution-NonCommercial-ShareAlike 4.0 International
